As com­pa­nies grap­ple with how to best com­pete with — or voice con­cerns over — Chi­na’s grow­ing biotech prowess, craft­ing a po­lit­i­cal strat­e­gy has be­come...

Drug­mak­ers do not ex­pect third-par­ty man­u­fac­tur­ers to in­crease their psy­che­del­ic ser­vices just yet, even af­ter Pres­i­dent Don­ald Trump is­sued an ex­ec­u­tive or­der de­signed to ex­pe­dite...

A San Fran­cis­co biotech look­ing to build out a suite of oph­thal­mol­o­gy- and car­di­ol­o­gy-fo­cused "af­fil­i­ate com­pa­nies" has raised $190 mil­lion.

Os­an­ni Bio dis­closedthe Se­ries...

The fail­ure of a Pfiz­er an­ti­body-drug con­ju­gate in its im­por­tant late-stage lung can­cer test is ex­act­ly what the New York drug­mak­er didn’t need.

The as­set...

Wear­able com­pa­ny Oura is part­ner­ing with Lil­ly­Di­rect, Eli Lil­ly’s di­rect-to-con­sumer tele­health plat­form, in hopes of help­ing pa­tients on GLP-1 weight loss med­ica­tions track changes in...